Marie Desportes

Essling Capital SAS (Essling Capital) is an independent private equity firm founded in 2016 by Frank-Noël Vandenberghe. The firm is headquartered in Paris, France.

Extens SAS (Extens) is an independent venture capital firm headquartered in Paris, France. The firm was founded by Arnaud Houette and Quentin Jacomet in 2013.

Sofimac Innovation SAS is an independent, early-stage venture capital firm which was created in 1998 by Eric Harlé and Didier Moret. Headquartered in Paris, France, Sofimac Innovation manages venture capital funds which provide equity financing for start-ups and early-stage companies in the Information and Communication Technologies (Software, SaaS, Multimedia and Telecom) sector.

Naxicap Partners SA operates as a private equity firm. It invests in hospitals, pharmaceuticals, business services, information technology, textile, and consumer goods sectors. The company was founded in 1995 and is headquartered in Paris, France.

Siparex XAnge Venture SAS is an Independent Venture Capital firm founded in 1977 by Benjamin Teszner. Siparex XAnge Venture SAS is headquartered in Paris.

Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa.

Aterovax SA develops in vitro diagnostic products for the management and assessment of cardiovascular diseases. Its products include diagnostic blood tests for determining and measuring activity of the cardiovascular biomarkers secretory phospholipase A2 (sPLA2) and secretory phospholipase A2-IIA (sPLA2-IIA) which provide physicians clinical information about the presence of a destabilized atherosclerotic plaque. The company was founded by Alain Tedgui, Ziad Mallat, Philippe Gabriel Steg, Joelle Benessiano and Jean-Marie Freyssinet on June 29, 2006 and is headquartered in Paris, France.

BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland.

Matignon Investissement et Gestion SAS (MIG) is an independent management-owned private equity investment firm based in Paris. MIG was established in 1996 through a management buy-out of Acmer from Banque Worms, formerly part of AXA-UAP and acquired by Deutsche Bank AG in 2001. Following the acquisition, Acmer was delisted. MIG manages private equity and venture capital funds, both generalist and sector specific.

A Plus Finance SA (A Plus Finance) is a private equity firm. The firm is founded in 1998 by Niels Court Payen andFrédéric Bayol. The firm headquartered in Paris, France.

Ventech SA is part of the venture capital arm and a wholly-owned subsidiary of Natixis Private Equity (NPE), which in turn is a subsidiary of Paris-based Natixis SA (XP: KN). Ventech was established in 1998 and is located in Paris. The firm specializes in technology venture capital investing. Ventech manages venture capital funds for a clientele of European institutional investors, with NPE as their sponsor. The firm relies on international strategic alliances with seeding funds and venture capital firms in Germany, Switzerland, Israel, Japan and the US.

Brainever SAS manufactures pharmaceutical products. It develops medicines for nervous system diseases. The company was founded on March 31, 2015 and is headquartered in Paris, France.

Kaneka Eurogentec SA distributes reagents, kits and other related products for the biotechnology, pharmaceutical, and diagnostic sectors. It offers a range of services, from basic research in genomics and proteomics, to services associated with the development and manufacture of diagnostic and therapeutic products. The company was founded in 1985 and is headquartered in Seraing, Belgium.

Stimulus SAS is a holding company, which provides consulting services for management and health at work. It offers anti-stress tools to companies. The company was founded by Patrick Légeron in 1989 and is headquartered in Paris, France.

BrainTale SAS engages in the development and distribution of diagnosis and prognosis tools for brain injured patients. Its products include BrainQuant and BrainScore-coma. The company was founded by Vincent Perlbarg, Julie Rachline, Didier Cassereau, Louis Puybasset, Damien Galanaud, and Lionel Velly on July 6, 2018 and is headquartered in Paris, France.

Prezioso Linjebygg SAS provides anti-corrosion coating and industrial insulation services. The firm also offers insulation and a range of coatings for structural, industrial and building applications. The company was founded in 1957 and is headquartered in Vienne, France.

XAnge Private Equity SA (XAnge Private Equity) is a private equity portfolio management firm which was created in 2003 by La Poste and ABN AMRO and is headquartered in France.

Geneo Capital Entrepreneur SA is an Independent Private Equity/Venture Capital firm founded in 2018 by Fanny Letier. Geneo Capital Entrepreneur SA is headquartered in Neuilly-sur-Seine.

Paluel-Marmont Capital SA (PMC) is the wholly-owned private equity subsidiary of Compagnie Lebon (XP: LBON) in France. Formerly known as Lebon Développement, the firm was established in 1991. Located in Paris, PMC invests their own equity in leveraged buy-outs in small- and mid-size businesses, sharing their professional expertise and business network with investee company management.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.